From the publishers of JADPRO

Metastatic HER2-Positive Breast Cancer Resource Center


Long term follow-up of the randomized MetaspHER study comparing intravenous versus subcutaneous trastuzumab in patients with HER2-positive metastatic breast cancer

Last Updated: Sunday, September 10, 2023

Data from the final analysis of the MetaspHER trial—which studied preference of subcutaneous (H-SC) vs intravenous (H-IV) trastuzumab among patients with HER2-positive metastatic breast cancer—showed that safety was consistent with the known H-IV and H-SC profiles and that there was no safety concern associated with prolonged exposure to H-SC. In the trial, 113 patients were randomly assigned to receive 3 cycles of 600 mg fixed-dose H-SC, followed by 3 cycles of standard H-IV, or the reverse sequence, and after the cross-over period, all patients except two pursued H-SC.

Clinical Breast Cancer
News & Literature Highlights

Nature Reviews Drug Discovery

Targeting HER2-positive breast cancer: advances and future directions

ESMO Congress 2022 Abstract

Final overall survival (OS) for abemaciclib plus trastuzumab +/- fulvestrant versus trastuzumab plus chemotherapy in patients with HR+, HER2+ advanced breast cancer (monarcHER): A randomized, open-label, phase II trial

ESMO Congress 2022 Abstract

Clinical safety and pharmacokinetics (PK) data of DZD1516, an BBB-penetrant selective HER2 inhibitor for the treatment of HER2-positive metastatic breast cancer

ESMO Congress 2022 Abstract

Quality of life and neurocognitive function in patients with active brain metastases of HER2-positive breast cancer treated with trastuzumab-deruxtecan

Cancer Network

Early efficacy observed with trastuzumab deruxtecan ± pertuzumab for HER2+ metastatic breast cancer

Oncology Nursing News

DESTINY-Breast02 confirms benefit of trastuzumab deruxtecan in previously treated patients with HER2+ metastatic breast cancer

Targeted Oncology

Safety of tucatinib triplet for HER2+ breast cancer sealed in real-world analysis

The ASCO Post

T-DXd confirmed as preferred second-line therapy for metastatic HER2-positive breast cancer

Clinical Breast Cancer

A phase II single-arm study of palbociclib in patients with HER2-positive breast cancer with brain metastases and analysis of ctDNA in patients with active brain metastases

Frontiers in Oncology

Treatment strategies for hormone receptor-positive, human epidermal growth factor receptor 2-positive (HR+/HER2+) metastatic breast cancer: A review